Rationale: Acinar cell carcinomas (ACCs) and mixed acinar-endocrine carcinomas (MAECs) of the pancreas are rare, accounting for only 1% of pancreatic tumors. Although both typically present at an advanced stage, chemotherapeutic regimes have not yet been standardized.
Introduction
Acinar cell carcinomas (ACCs) of the pancreas are rare, and account for only 1% of pancreatic exocrine tumors. [1] ACCs may express endocrine markers such as chromogranin and synaptophysin in a limited number of cells. ACCs with the expression of endocrine markers in >30% of cancer cells are referred to as mixed acinar-endocrine carcinomas (MAECs). [2, 3] Due to their rarity, a treatment protocol for unresectable MAECs has not yet been standardized.
We herein present a 65-year-old man with MAEC, who showed a partial response (PR) for 12 months with S-1 chemotherapy. These results suggest that S-1 chemotherapy may be effective for MAEC of the pancreas.
Case report
A 65-year-old man with no particular previous medical history presented with persistent epigastric pain for 1 month. He did not have a family history of pancreatic cancer. His physical examination was unremarkable. Laboratory tests revealed elevations in hepatobiliary enzymes and slight renal dysfunction: gamma-glutamyl transpeptidase (116.0 U/L; normal range: 12-70 U/L), alkaline phosphatase (762.0 U/L; normal range: 110-370 U/L), creatinine (107.8 mmol/L; normal range: 54-92 mmol/ L), and the estimated glomerular filtration rate (47.1 mL/min/ 1.73 m 2 ; normal range: 60 < mL/min/1.73 m 2 ). He also had elevated levels of carbohydrate antigen 19-9 (56.6 U/mL; normal range: <37.0 U/mL), carcinoembryonic antigen (17.2 mg/L; normal range: <5.0 mg/L), and Span-1 (73.0 U/mL; normal range: <30.0 U/mL), while DUPAN-2 was within the normal range (44 U/mL; normal range: <150 U/mL). He underwent abdominal computer tomography (CT), which revealed an 8.0-cm mass in the tail of the pancreas and multiple liver metastases (Fig. 1A) . On endoscopic ultrasound, the lesion appeared to be a hypovascular tumor surrounded by the pancreatic parenchyma with increased blood flow. Endoscopic ultrasound-guided fine needle aspiration biopsy was attempted, but was not diagnostic because of its small size.
Based on imaging features and elevations in tumor markers, chemotherapy was initiated for suspected ductal carcinoma of the pancreas, with gemcitabine being administered at a dose of 700 mg/m 2 on days 1, 8, and 15, of every 28-day cycle. After 7 courses, the primary pancreatic tumor and liver metastases both appeared to be progressive on CT (Fig. 1B) . S-1 was administered orally at a daily dose of 80 mg/m 2 from days 1 to 28 of each 42-day cycle. Due to the development of side effects such as nausea and a poor appetite, the protocol was changed to daily administration for 2 weeks with a 2-week interval as a cycle. The first follow-up CT after starting S-1 showed an approximately 38% reduction in the size of the primary tumor and liver metastases, according to the Response Evaluation Criteria In Solid Tumors (RECIST) protocol. [4] After PR had been sustained for 12 months after the initiation of S-1 chemotherapy (Fig. 1C) , tumors started increasing in size.
Percutaneous liver biopsy was performed in order to evaluate chemotherapeutic effects on tissue. The liver biopsy specimen consisted predominantly of viable cancer cells arranged in an acinar or trabecular pattern. The cells had round, enlarged nuclei, and occasional mitotic figures. On immunostaining, cells were diffusely positive for BCL10 (a marker for acinar cells), chromogranin A, and synaptophysin, leading to the diagnosis of MAEC (Fig. 2) .
Chemotherapy with cisplatin (65 mg/m 2 on day 1) and etoposide (80 mg/m 2 on days 1-3) was administered as a third-line treatment. However, leukopenia (1300 leukocytes/ mm 3 ) with neutropenia (520 neutrophils/mm 3 ) developed on day 16. Therefore, chemotherapy was discontinued and the treatment plan was switched to best supportive care.
Discussion
The pancreas consists of exocrine and endocrine components. Although acinar tissue accounts for >90% of the entire pancreas, ACCs account for only 1% of pancreatic tumors. Furthermore, MAECs are markedly rarer with only several dozen cases being described in the literature. According to a recent literature review by Liu et al, [5] MAECs are often diagnosed in middle-aged individuals with a male predominance, and may develop in any part of the pancreas, with ∼50% being located in the pancreatic head.
Histologically, MAECs are positive for both acinar (e.g., trypsin, chymotrypsin, lipase, and BCL10) and endocrine markers (e.g., chromogranin A and synaptophysin). MAECs may be divided into 2 groups based on histological appearance: One is a collision tumor, in which acinar and endocrine components are relatively separated, while the other is intermingled tumors consisting of cancer cells with both acinar and endocrine phenotypes. [6] The presented case corresponded to the latter group because tumor cells were diffusely positive for chromogranin A, synaptophysin, and BCL10.
A standardized management protocol for pancreatic MAECs has not yet been established. It is generally agreed that surgery is the sole curative therapy for resectable tumors. [1] In a literature review by Holen et al, [7] patients who underwent surgery (n = 16) as first-line therapy had longer survival (36 months) than those who had nonsurgical treatments (n = 21, 14 months). Tumor recurrence was observed in approximately 50% of R0, 75% of R1, and ∼100% of R2 patients, indicating that micrometastases were already present even in clinically resectable MAECs. The rarity of MAECs has also restricted the discussion of appropriate chemotherapy for unresectable cases. Since MAECs have 2 cellular components, chemotherapy regimens that are effective for both elements are ideal. Previous case studies indicated that fluorouracil-based regimens are effective against ACCs. [7, 8] Holen et al [7] also analyzed 22 different chemotherapy regimens used in 18 patients. None of the patients examined showed a complete response (CR), while PR was observed in 2 patients and stable disease (SD) in 7. Of the 2 patients with PR, 1 was administered a combination of irinotecan, fluorouracil, and leucovorin, while the other received an experimental regimen of cytarabine, cisplatin, and caffeine. The most common chemotherapy associated with SD was fluorouracil. [7] In another study by Seki et al, [8] 1 out of 3 patients receiving S-1 (an oral prodrug of fluorouracil) achieved PR, while 4 patients who received gemcitabine had limited effects.
Based on these findings, fluorouracil may be more likely to exert therapeutic effects in ACCs than gemcitabine. Abraham et al [9] reported that the loss of Smad4 protein expression or p53 accumulation was not detected in ACCs, highlighting a significant difference in genetic features between ACCs and pancreatic ductal adenocarcinomas. Since ∼25% of ACCs are known to have abnormalities in the APC/beta-catenin pathway that cause colorectal cancer, fluorouracil-based chemotherapies are expected to have an effect on ACCs.
In terms of chemotherapy for high-grade endocrine neoplasms of the pancreas, combination chemotherapy using cisplatin and etoposide is currently the first choice. [10] [11] [12] However, several case reports also showed that S-1 was effective for patients with highgrade endocrine neoplasms of the pancreas. [13] [14] [15] [16] [17] A single case of MAEC treated with S-1 is available in the literature. Kanemasa et al [18] treated a 63-year-old man with advanced pancreatic MAEC and multiple liver metastases using S-1. Liver biopsy from a metastatic deposit, which was performed before treatment was initiated, showed the features of ACC with only a small number of chromogranin-positive cells. Chemotherapy with S-1 (80 mg/m 2 per day) led to a 10-month PR with the primary tumor and liver metastases being markedly reduced in size. After tumor progression was observed, gemcitabine was administered, but was not effective. He eventually died of liver failure 18 months after the initiation of S-1 chemotherapy. At autopsy, tumor morphology was nearly identical to that observed in pretreatment liver biopsy; however, the immunophenotype changed with endocrine features being positive in >30% tumor cells expressing chromogranin. The diagnosis was then revised to MAEC. The authors suspected that S-1 was less effective for the endocrine element than for the ACC component.
In our case, a histological diagnosis was not established before the initiation of chemotherapy. Since gemcitabine was less effective, S-1 was administered and led to a 12-month PR. At that point, we obtained tissue confirmation of the diagnosis of MAEC, and suspected that tumor regrowth was induced by the endocrine component, which was resistant to S-1. Therefore, chemotherapy with cisplatin and etoposide was initiated, but shortly stopped because of the development of side effects.
Based on the clinical courses of our case and the patient reported by Kanemasa et al, [18] we initially thought that MAECs may respond to S-1 chemotherapy, similar to ACCs. Another possibility is that S-1 therapy induced endocrine differentiation in ACCs of the pancreas during the drug-resistance process. In the case reported by Kanemasa et al the number of cancer cells expressing endocrine markers dramatically increased after S-1 chemotherapy. Although pretreatment biopsy was not available in our patient, posttreatment biopsy showed both acinar and endocrine differentiation. Therefore, a potential interesting interpretation is that S-1 chemotherapy showed PR when the condition was ACC, and eventually showed decreased effectiveness when the condition shifted to MAEC. Further studies using matched pre-and posttreatment biopsies are needed to conclude which possibility is more likely. In conclusion, this report indicates that some cases of MAECs show a good response to S-1 chemotherapy, similar to ACCs. However, future studies are necessary to conclude whether S-1 chemotherapy truly works against MAECs or induces endocrine differentiation in ACCs as a part of the drug-resistance process.
